Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed. MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).
| Website | https://www.mladx.com/ |
| Employees | 10 (4 on RocketReach) |
| Founded | 2019 |
| Technologies |
JavaScript
,
HTML
,
PHP
+4 more
(view full list)
|
| Industry | Medical Equipment Manufacturing |
| Keywords | Skin Cancer Diagnostics, Cancer Diagnostics, Oncology Diagnostics, Cancer Risk Assessment, Pathology Testing, Cancer Testing, Cancer Biomarkers, Molecular Diagnostics, Precision Oncology, Disease Diagnostics, Medical Diagnostics, Clinical Diagnostics, Diagnostic Tests, Medical Testing, Health Diagnostics |
| Competitors | Quest Diagnostics, Labcorp, Roche, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, PerkinElmer, Inc., Abbott, BD, Fujirebio Europe +35 more (view full list) |
Looking for a particular MLA Diagnostics employee's phone or email?
4 people are employed at MLA Diagnostics.